@conference{
author = "Todorović, Lidija and Milovanović, Jelena and Mandušić, Vesna and Živaljević, Vladan and Paunović, Ivan and Stanojević, Boban",
year = "2023",
abstract = "Background: Thyroid neoplasms include benign tumors – thyroid adenoma (TA), and malignant tumors of various histological types: papillary thyroid carcinoma (PTC) – the most common and usually indolent, anaplasƟ c thyroid carcinoma (ATC) – the most aggressive, and several other types such as follicular, medullary and poorly diff erenƟ ated. Despite the progress in understanding the epidemiology and geneƟ c landscape of thyroid tumors, the diagnosis, prognosis and treatment approach require further improvement. Interleukin-6 (IL-6) is a pro-infl ammatory cytokine with a central role in the regulaƟ on of immune and infl ammatory responses including autoimmune thyroid diseases. Studies have revealed a potenƟ al impact of IL-6 in the development, progression and control of thyroid cancer. The aim of this study was to provide novel aspects for the preoperaƟ ve diff erenƟ al diagnosis and/or prognosis of thyroid cancer. To achieve this, we assessed the circulaƟ ng levels of IL-6 in paƟ ents with benign and malignant thyroid tumors of various histotypes, compared them with healthy volunteers, and correlated the results with clinicopathological parameters. PaƟ ents and Methods: The study included 43 paƟ ents with benign or malignant thyroid tumors, surgically treated at the Center for Endocrine Surgery, Clinical Center of Serbia. IL-6 protein levels were determined in plasma samples by quanƟ taƟ ve ELISA. Parametric and nonparametric staƟ sƟ cal tests were used for data analysis. Results: IL-6 concentraƟ ons in paƟ ents with either TA or carcinoma (PTC, ATC) were signifi cantly higher compared to the healthy volunteers (Mann Whitney test). The highest concentraƟ ons were detected in ATC paƟ ents (Median±SD 15.97±0.71 pg/mL), being signifi cantly higher compared to TA and PTC (2.14±1.34 pg/mL and 1.96±2.12 pg/mL, respecƟ vely). In PTC microcarcinoma, IL-6 was higher compared to controls, but there was no signifi cant diff erence compared to other PTC or TA (Mann Whitney test). The correlaƟ on analysis with clinicopathological parameters in PTC paƟ ents revealed a trend towards the associaƟ on of increased IL-6 plasma levels with the presence of nodal and distant metastases. No other signifi cant associaƟ ons were found. Conclusion: PaƟ ents with thyroid adenoma or carcinoma have increased plasma IL-6 levels that are in proporƟ on with the aggressiveness of the thyroid tumor, suggesƟ ng that IL-6 might be a candidate biomarker for diagnosis and prognosis of thyroid neoplasms.",
publisher = "Belgrade : Serbian Association for Cancer Research",
journal = "Oncology Insights",
title = "Interleukin-6, a potential plasma biomarker for diagnosis and prognosis of thyroid neoplasms",
number = "1",
pages = "83-83",
url = "https://hdl.handle.net/21.15107/rcub_vinar_12634"
}
